A multicentre, prospective, observational cohort study to assess the effects of vildagliptin relative to sulphonylurea as dual therapy with metformin (or as monotherapy*) in Muslim patients with type 2 diabetes fasting during Ramadan: VIRTUE

Trial Profile

A multicentre, prospective, observational cohort study to assess the effects of vildagliptin relative to sulphonylurea as dual therapy with metformin (or as monotherapy*) in Muslim patients with type 2 diabetes fasting during Ramadan: VIRTUE

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jan 2017

At a glance

  • Drugs Vildagliptin (Primary) ; Glimepiride
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms VIRTUE
  • Sponsors Novartis
  • Most Recent Events

    • 01 Sep 2016 Results of pooled data (n=246) published in the Diabetes Therapy (2016).
    • 19 Sep 2014 Results of a post-hoc analysis were presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
    • 16 Sep 2014 Primary endpoint has been met (Proportion of patients with 1 hypoglycaemic event during Ramadan) according to results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top